

Teresa Troiani

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2704264/teresa-troiani-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

2,994
citations

31
h-index

53
g-index

104
ext. papers

3,440
ext. citations

6.4
avg, IF

4.61
L-index

#	Paper	IF	Citations
99	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
98	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 109	12.8	0
97	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. <i>Frontiers in Immunology</i> , 2022 , 13, 804597	8.4	4
96	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. <i>Cancer Treatment Reviews</i> , 2022 , 105, 102373	14.4	0
95	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series.. <i>Healthcare (Switzerland)</i> , 2022 , 10,	3.4	1
94	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	0
93	NMR Profiling of Identifies Cytotoxic Compounds against Cetuximab-Resistant Colon Cancer Cell Lines. <i>Molecules</i> , 2021 , 26,	4.8	1
92	Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3578-3578	2.2	2
91	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021 , 11, e2021165S	1.5	
90	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 15	12.8	6
89	Dual inhibition of TGF β and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021 , 38, 24	3.7	2
88	Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. <i>Cancers</i> , 2021 , 13,	6.6	1
87	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 227-235	3.8	2
86	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021 , 157, 250-258	7.5	6
85	Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	12
84	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. <i>ESMO Open</i> , 2020 , 5,	6	6
83	Baseline IFN γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020 , 10, 17626	4.9	3

82	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 138, 1-10	7.5	9
81	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2020 , 4, e000813	6	20
80	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. <i>British Journal of Cancer</i> , 2020 , 122, 1782-1790	8.7	3
79	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102023	14.4	19
78	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. <i>Cancers</i> , 2019 , 11,	6.6	6
77	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 41	12.8	37
76	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 236	12.8	12
75	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 178	12.8	19
74	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 845-855	6.1	30
73	Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management. <i>Open Medicine (Poland)</i> , 2019 , 14, 761-766	2.2	18
72	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000519	6	3
71	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. <i>ESMO Open</i> , 2019 , 4, e000551	6	11
70	Use of Rituximab in NHL Malt Type Pregnant in I st Trimester for Two Times. <i>Open Medicine (Poland)</i> , 2019 , 14, 757-760	2.2	19
69	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 810-820	8.9	19
68	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018 , 17, 30	42.1	34
67	Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. <i>Scientific Reports</i> , 2018 , 8, 5309	4.9	26
66	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. <i>Oncotarget</i> , 2018 , 9, 19273-19382	3.9	5
65	Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases. <i>Open Medicine (Poland)</i> , 2018 , 15, 22-26	2.2	14

64	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018 , 23, 1178-1187	5.7	31
63	Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review. <i>BMC Surgery</i> , 2017 , 17, 38	2.3	24
62	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. <i>Cancer Treatment Reviews</i> , 2017 , 53, 61-69	14.4	77
61	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. <i>Medical Oncology</i> , 2017 , 34, 186	3.7	5
60	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017 , 8, 82773-82783	3.3	5
59	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017 , 2, e000177	6	19
58	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017 , 23, 4675-4688	5.6	70
57	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017 , 8, 23020-23032	3.3	26
56	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017 , 8, 67592-67604	3.3	11
55	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 68305-68316	3.3	20
54	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. <i>ESMO Open</i> , 2016 , 1, e000088	6	69
53	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6345-61	5.6	69
52	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. <i>Oncotarget</i> , 2016 , 7, 4265-78	3.3	51
51	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. <i>Clinical Cancer Research</i> , 2015 , 21, 2975-83	12.9	51
50	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 4686-97	12.9	93
49	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 217-224	1	1
48	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015 , 21, 4153-64	12.9	13
47	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3634-TPS3634	2.2	2

46	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS789-TPS789	2.2	1
45	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 23281-96	3.3	45
44	The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15224-e15224	2.2	
43	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 279-287	1	
42	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 809-21	5.9	21
41	Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. <i>Clinical Cancer Research</i> , 2014 , 20, 3775-86	12.9	76
40	Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2014 , 3, 299-308	0.8	
39	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15256-e15256	2.2	
38	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 160-160	2.2	
37	Metformin in lung cancer: rationale for a combination therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 1401-9	5.9	22
36	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 241-55	5.4	44
35	Emerging VEGF-receptor inhibitors for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 25-37	3.7	24
34	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. <i>International Journal of Cancer</i> , 2013 , 133, 2089-101	7.5	70
33	Increased TGF- β s a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. <i>Clinical Cancer Research</i> , 2013 , 19, 6751-65	12.9	111
32	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. <i>Therapeutic Advances in Medical Oncology</i> , 2013 , 5, 51-72	5.4	10
31	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. <i>Clinical Cancer Research</i> , 2013 , 19, 3508-19	12.9	88
30	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013 , 5, 49-55	3.6	5
29	Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell'Italia Meridionale (GOIM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14565-e14565	2.2	2

28	A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. <i>Angiogenesis</i> , 2012 , 15, 141-50	10.6	46
27	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 949-59	5.9	18
26	Clinical results with EGFR inhibitors in colorectal cancer 2012 , 44-59		
25	Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2011 , 71, 283-90	5.9	24
24	Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. <i>PLoS ONE</i> , 2011 , 6, e28841	3.7	34
23	Trastuzumab Resistance in Breast Cancer 2011 , 51-60		
22	Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. <i>Clinical Cancer Research</i> , 2010 , 16, 4990-5001	12.9	70
21	Resistance mechanisms of tumour cells to EGFR inhibitors. <i>Clinical and Translational Oncology</i> , 2009 , 11, 270-5	3.6	17
20	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1698-707	6.1	22
19	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 65, 200-11	7	50
18	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. <i>World Journal of Surgical Oncology</i> , 2007 , 5, 42	3.4	9
17	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2007 , 2, 335-48	6.2	3
16	Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. <i>Clinical Cancer Research</i> , 2007 , 13, 6450-8	12.9	36
15	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 236-241	0.4	
14	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 117-126	0.4	
13	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. <i>Targeted Oncology</i> , 2006 , 1, 123-129	5	3
12	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006 , 208, 344-53	7	54
11	Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1883-94	6.1	37

10	Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7099-107	12.9	47
9	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. <i>Oncologist</i> , 2006 , 11, 274-84	5.7	78
8	Antiangiogenic drugs in non-small cell lung cancer treatment. <i>Current Opinion in Oncology</i> , 2006 , 18, 1514-21	12.9	17
7	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. <i>Endocrine-Related Cancer</i> , 2005 , 12 Suppl 1, S159-71	5.7	76
6	Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. <i>Clinical Cancer Research</i> , 2005 , 11, 1268-76	12.9	25
5	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. <i>Clinical Cancer Research</i> , 2004 , 10, 784-93	12.9	309
4	Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. <i>Clinical Cancer Research</i> , 2003 , 9, 866-71	12.9	37
3	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. <i>Clinical Cancer Research</i> , 2003 , 9, 1546-56	12.9	229
2	Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). <i>Clinical Cancer Research</i> , 2002 , 8, 3250-8	12.9	164
1	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. <i>International Journal of Cancer</i> , 2001 , 93, 172-8	7.5	79